<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4853">
  <stage>Registered</stage>
  <submitdate>20/01/2015</submitdate>
  <approvaldate>20/01/2015</approvaldate>
  <nctid>NCT02349126</nctid>
  <trial_identification>
    <studytitle>Study of ARC-520 in Patient With Chronic Hepatitis B Virus</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>Heparc-2005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ARC-520 Injection

Experimental: Treatment Group - ARC-520 Injection


Treatment: drugs: ARC-520 Injection
ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy: To evaluate the depth and duration of HBsAg decline in response to a single dose of ARC 520 in combination with entecavir or tenofovir in patients with chronic HBV infection</outcome>
      <timepoint>Through Day 85 post-dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety:To determine the safety and tolerability of ARC 520 through monitoring of adverse events, vital signs, physical exam changes, blood sampling for hematology, coagulation and chemistry and 12-lead ECGs</outcome>
      <timepoint>Through Day 85 post-dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters: Cmax, AUC0-24, AUClast, AUCinf, CL, V=CL/kel, kel, t1/2 - Blood samples collected immediately prior to infusion and immediately prior to end of infusion, and 0.5,1,3,6,24,48 hrs post-infusion.</outcome>
      <timepoint>Post dosing on Days 1,2 &amp; 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Allergenicity:Evaluate Allergenicity of ARC-520 through Bee Venom Allergy Test (IgE)</outcome>
      <timepoint>Within 30 days prior to first dose and at Day 29</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, 18 to 65 years of age

          -  Written informed consent

          -  No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment

          -  No abnormal finding of clinical relevance

          -  Diagnosis of immune active chronic HBV infection

          -  &gt; 6 months of continuous treatment with daily, oral entecavir or tenofovir</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating

          -  Acute signs of hepatitis/other infection within 4 weeks of screening

          -  Antiviral therapy other than entecavir or tenofovir within 3 months of screening

          -  Prior treatment with interferon or a toll receptor agonist in last 12 months

          -  Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants

          -  Use of dietary and/or herbal supplements that can interfere with liver metabolism

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism

          -  Use of prescription medication or over-the-counter products

          -  Depot injection/implant of any drug except birth control.

          -  Known diagnosis of diabetes mellitus.

          -  History of autoimmune disease

          -  Human immunodeficiency virus (HIV) infection

          -  Sero-positive for HCV, and/or history of delta virus hepatitis

          -  Hypertension: blood pressure &gt; 150/100 mmHg

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome/unexplained sudden cardiac death

          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe
             cardiovascular disease

          -  History of malignancy, except adequately treated basal cell carcinoma, squamous cell
             skin cancer, superficial bladder tumors, in situ cervical cancer

          -  Major surgery within 3 months of screening

          -  History of alcohol and/or drug abuse &lt; 12 months from screening

          -  Regularly uses alcohol within past 6 months (ie, more than 14 units of alcohol per
             week)

          -  Evidence of acute inflammation, sepsis, or hemolysis

          -  Diagnosed with a significant psychiatric disorder

          -  Use of drugs of abuse

          -  History of allergy to bee venom

          -  Use of investigational agents/devices within 30 days

          -  Current participation in an investigational study

          -  Clinically significant gastrointestinal pathology, unresolved gastrointestinal
             symptoms, liver or kidney disease

          -  History/presence of Gilbert's syndrome, conditions that interfere with absorption,
             distribution, metabolism, excretion of drugs

          -  Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction

          -  Clinically significant history/presence of uncontrolled systemic disease

          -  Donated blood (500 mL) within 7 days prior to study treatment administration

          -  History of fever within 2 weeks of screening

          -  Immunization/planned immunization with live attenuated vaccine except influenza
             vaccine

          -  Excessive exercise/physical activity within 7 days of screening/enrolment or during
             study

          -  History of coagulopathy or stroke within past 6 months, and/or concurrent
             anticoagulants</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network Ltd - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arrowhead Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with chronic HBV infection will receive ARC-520 in combination with entecavir or
      tenofovir and be evaluated for safety and efficacy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02349126</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>